When the immune system attacks the insulation — and the signals stop getting through

Building now. MS has strong research anchors already documented in the Master Reference — the Harvard military study, the EBV 32-fold risk increase, the EBNA2 autoimmune cascade work — all of it already cited on the ME/CFS page. I'll use those anchors here without duplicating the full ME/CFS treatment, and I'll cross-reference appropriately.

GRAIN FREE ME — Medical Library

grainfreeme.com • Autoimmune & Inflammatory Category

Multiple Sclerosis

When the immune system attacks the insulation — and the signals stop getting through

I'm not a doctor. I'm not telling you to change your medication. Everything on this page is personal testimony and links to real medical sources. Always work with a qualified physician. Always ask for the right test by name.

What it is

Multiple sclerosis is an autoimmune condition in which the immune system attacks myelin — the protective sheath that surrounds nerve fibers in the brain and spinal cord. Myelin is insulation. It does for nerve signals what the rubber coating does for electrical wire — it keeps the signal contained, directed, and fast. When the immune system strips that insulation away, the signals slow down, short circuit, or stop reaching their destination entirely.

The result is a condition that looks different in almost every person who has it, because the location of the damage determines the symptoms. Damage in the optic nerve produces vision problems. Damage in the cerebellum produces balance and coordination problems. Damage in the spinal cord produces weakness, numbness, or loss of bladder control. MS does not follow a single script because the immune attack does not follow a single path.

What it does follow is a pattern of inflammation and scarring. The word sclerosis means scarring. Multiple sclerosis means multiple areas of scarring — lesions distributed across the central nervous system, visible on MRI, each one representing a site where myelin was attacked and scar tissue formed in its place. Some of that damage partially repairs. Some does not.

MS affects approximately one million Americans — a number that has been revised upward as imaging and diagnostic criteria have improved. It is more common in women than men, at a ratio of approximately three to one, and is typically diagnosed between the ages of 20 and 50, though earlier and later diagnoses occur. Like every autoimmune condition covered in this library, it clusters — people with MS are at elevated risk for other autoimmune diagnoses, and genetic predisposition plays a meaningful role.

And then there is the EBV connection — which is no longer a hypothesis.

Symptoms

MS symptoms vary depending on which nerves are affected and how significantly. The unpredictability is not a quirk of the condition — it is the condition. No two people with MS have exactly the same picture.

Vision

• Optic neuritis — inflammation of the optic nerve producing blurred vision, pain with eye movement, or temporary vision loss, typically in one eye. This is frequently the first symptom that sends someone to a neurologist.

• Double vision

• Involuntary eye movements

Motor

• Weakness in one or more limbs — often asymmetric

• Spasticity — muscle stiffness and spasms

• Difficulty with coordination and balance

• Tremor

• Gait changes — dragging a foot, unsteady walking

Sensory

• Numbness or tingling — in the face, body, arms, or legs

• A sensation of an electric shock running down the spine when the neck is bent forward — called Lhermitte's sign, and considered a classic MS finding

• Pain — both nerve pain and musculoskeletal pain from altered movement patterns

Cognitive and psychological

• Cognitive slowing — difficulty with processing speed, memory, and concentration

• Brain fog

• Depression — both as a psychological response to the diagnosis and as a direct neurological effect of the disease

• Emotional lability in some patients

Autonomic

• Bladder dysfunction — urgency, frequency, incomplete emptying

• Bowel dysfunction

• Sexual dysfunction

• Temperature sensitivity — many MS patients find that heat significantly worsens symptoms, a phenomenon called Uhthoff's phenomenon

Fatigue MS fatigue is one of the most commonly reported and most disabling symptoms — a neurological fatigue distinct from ordinary tiredness, similar in character to the fatigue documented in ME/CFS and Sjogren's. It does not correlate neatly with visible disability level. Someone who appears functional can be profoundly fatigued by the same neurological process driving their other symptoms.

Disease course MS presents in several patterns. Relapsing-remitting MS — the most common form, affecting approximately 85% of people at diagnosis — involves discrete attacks followed by partial or complete recovery. Primary progressive MS involves steady worsening without distinct relapses. Secondary progressive MS begins as relapsing-remitting and transitions to progressive worsening over time. The course is not predictable at diagnosis, and the same disease can look very different a decade in.

History

The first clinical description of what we now recognize as MS is generally attributed to Jean-Martin Charcot, the French neurologist who in 1868 formally described the condition and connected the clinical symptoms to the pathological findings of plaques in the nervous system at autopsy. The name — sclérose en plaques — reflected exactly what he found: multiple areas of scarring throughout the central nervous system.

What Charcot could not know was why. For most of the century that followed, MS was understood as a disease of unknown cause, with inflammation as a feature but not yet a fully understood mechanism. The autoimmune hypothesis — that the immune system was attacking myelin as though it were foreign tissue — gained traction through the mid-20th century and is now the established framework.

MRI changed everything. Before MRI, MS diagnosis required clinical presentation of symptoms separated in time and location in the nervous system, with no reliable way to visualize the lesions directly. MRI made the lesions visible, transformed the speed and accuracy of diagnosis, and allowed researchers to watch disease activity in ways previously impossible.

Treatment development accelerated dramatically in the 1990s with the approval of the first disease-modifying therapies. Before that decade, there was no treatment proven to alter the course of MS. The treatment landscape now includes dozens of approved options across multiple mechanisms of action — a transformation in outcomes that happened within a single generation.

And then, in 2022, a landmark study changed the conversation about cause.

Researchers at Harvard, drawing on blood samples collected from more than 10 million United States military personnel tracked over two decades, found that risk of developing MS increased 32-fold following Epstein-Barr virus infection. The association was not found with other viruses — including cytomegalovirus, which spreads the same way EBV does. The lead researcher described it as the first study providing compelling evidence of causality. EBV is not sufficient on its own to cause MS — genetic predisposition matters, and most people infected with EBV do not develop MS — but the evidence that EBV is involved in triggering MS in genetically susceptible people is no longer speculative. It is documented, peer-reviewed, and published in one of the most respected scientific journals in the world.

This connects directly to the broader EBV-autoimmune picture documented on the ME/CFS page. The same EBNA2 protein that researchers at Cincinnati Children's Hospital found binding to genome locations associated with seven autoimmune diseases — including MS — appears to be part of how EBV infection can trigger autoimmune activation in people carrying specific genetic risk. The immune system that cannot fully clear a latent herpesvirus keeps searching. In some people, that search turns against the body's own tissue. In MS, that tissue is myelin.

What you can do about it

MS has established, effective disease-modifying treatments — more of them than almost any other autoimmune condition in this library. Early treatment meaningfully changes long-term outcomes. This is not a no-treatment diagnosis.

Disease-modifying therapies — DMTs The goal of DMTs is to reduce the frequency and severity of relapses, slow the accumulation of new lesions, and delay progression. Options range from injectable interferons and glatiramer acetate — the original approved therapies from the 1990s — to oral medications including dimethyl fumarate, fingolimod, and siponimod, to high-efficacy infusion therapies including natalizumab, ocrelizumab, and alemtuzumab. The choice of therapy is individualized based on disease activity, MRI findings, patient factors, and risk tolerance. Higher efficacy therapies carry higher risk profiles and require more intensive monitoring.

Relapse management Acute relapses are typically treated with high-dose corticosteroids to shorten the duration and reduce inflammation. Steroids do not change long-term outcomes — they are a bridge through the acute event.

Symptom management Individual symptoms — spasticity, fatigue, pain, bladder dysfunction, depression — each have their own management strategies. MS care at a comprehensive center typically involves neurology, physical therapy, occupational therapy, urology, and mental health support working in coordination.

Lifestyle factors Vitamin D deficiency is associated with increased MS risk and disease activity — supplementation is commonly recommended, with levels monitored. Smoking is associated with worse outcomes and faster progression — cessation matters. Exercise, adapted to current function level, supports neurological health and quality of life.

Ask for the right test by name:

• MRI of the brain and spinal cord with and without contrast — the primary diagnostic tool. Lesions must be disseminated in space and time for MS diagnosis.

• Visual evoked potentials — measures the speed of signal transmission through the optic nerves. Can detect subclinical optic nerve involvement.

• Lumbar puncture — cerebrospinal fluid analysis for oligoclonal bands, present in approximately 90% of MS patients. Not always required but supports diagnosis when MRI findings are incomplete.

• Referral to neurology — MS diagnosis and management requires neurological expertise. A general practitioner cannot carry this workup alone.

• VItamin D level — 25-OH vitamin D — both as a baseline and for ongoing monitoring

A single episode of neurological symptoms — even a clear episode of optic neuritis — is not a diagnosis of MS. The diagnosis requires demonstration of disease disseminated across multiple areas of the nervous system and across time. That process takes careful evaluation and should not be rushed in either direction.

Perfect. So the full picture is:

• Neurological symptoms significant enough that MS was the working theory

• Symptoms resolved or improved meaningfully once HFI was identified and fructose removed and triglycerides came down

• The connection between hypertriglyceridemia and the neurological symptom picture was never named by any physician — you connected those dots yourself in retrospect

That's personal testimony and retrospective observation — written exactly that way. No clinical claim. Just honest documentation of what happened in sequence and what it looks like looking back.

And it's genuinely useful clinical information. Hypertriglyceridemia-induced peripheral neuropathy is a documented mechanism — severely elevated triglycerides can damage peripheral nerves directly. The fact that no physician in the 28-doctor loop connected those two things is not surprising given the history. The fact that the neurological picture improved when the upstream cause was addressed is the data point that matters.

Here is the revised personal note:

Personal note

This one was personal in a way the others weren't.

There was a period — before the HFI diagnosis, before the ME/CFS picture became clear — where almost every symptom I was carrying pointed more toward MS than anything else. The neurological picture was that complete. Muscles wrong. Nerves wrong. The kind of symptom stack that lands you in a neurologist's office with MS on the table as the working theory.

What nobody connected at the time was the triglycerides. Severely elevated triglycerides are documented to cause peripheral nerve damage directly — hypertriglyceridemia-induced neuropathy is a real mechanism, not a fringe hypothesis. My triglycerides were significantly elevated throughout that entire period, flagged in labwork, and never once discussed in the context of the neurological symptoms I was describing. Statins were offered. Fenofibrate — the medication actually indicated for triglycerides — had to be fought for. The neurological symptoms and the metabolic findings sat in separate folders and nobody put them on the same desk.

Once HFI was identified, fructose came out, and triglycerides came down — the neurological picture changed. I made that connection myself, in retrospect, after the fact. No physician named it. No one drew that line. I drew it looking backward at the sequence of events once I finally had enough of the picture to see it.

I am not saying I had MS and fixed it with diet. I am saying I had a neurological symptom picture severe enough to put MS on the differential, an upstream metabolic cause that was documented and never addressed, and a resolution that followed when the upstream cause was finally treated. Those are three documented facts in sequence. What they mean is worth discussing with a physician who is willing to look at the whole stack at once.

If you are in the neurological symptom loop right now — and your triglycerides are elevated — make sure someone has specifically connected those two things before you accept a diagnosis that requires a different explanation. Ask about hypertriglyceridemia and peripheral neuropathy by name. Ask whether the metabolic picture has been fully addressed before the neurological one gets its final label.

The "When They Stack" page exists because this exact situation — two findings sitting in separate folders that belong on the same desk — is not rare. It is the rule.

Sources

• National Multiple Sclerosis Society: nationalmssociety.org

• National Institute of Neurological Disorders and Stroke (NINDS) — Multiple Sclerosis: ninds.nih.gov

• Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301. PubMed PMID: 35025605

• Harley JB, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nature Genetics. 2018;50(5):699–707. PubMed

• Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology. 2018;17(2):162–173. PubMed PMID: 29275051

• Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336–1346. PubMed PMID: 27889190

• Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nature Reviews Neurology. 2017;13(1):25–36. PubMed PMID: 27934854